Kezar Life Sciences (KZR) Q2 2024 earnings summary

Executive summary

• Focused on developing small molecule therapeutics for immune-mediated diseases and cancer, with lead candidate zetomipzomib in Phase 2b for lupus nephritis and Phase 2a for autoimmune hepatitis; oncology candidate KZR-261 Phase 1 enrollment stopped to reallocate resources.

• Completed enrollment in the PORTOLA Phase 2a trial for autoimmune hepatitis, with topline data expected in H1 2025.

• PALIZADE Phase 2b trial for zetomipzomib in lupus nephritis is ongoing, targeting 279 patients, with topline data expected mid-2026.

• Collaboration with Everest Medicines for development and commercialization of zetomipzomib in Greater China and parts of Asia, with recent amendment to cost-sharing terms.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $164.2 million as of June 30, 2024, down from $201.4 million at year-end 2023.

• Net loss was $21.5 million ($0.30/share) for Q2 2024, compared to $24.3 million ($0.34/share) in Q2 2023; net loss for the first six months was $43.2 million.

• Research and development expenses decreased to $16.3 million in Q2 2024 from $21.0 million in Q2 2023, reflecting restructuring and prioritization.

• General and administrative expenses were $5.6 million in Q2 2024, slightly down from $5.8 million in Q2 2023.

• Restructuring and impairment charges of $1.5 million in Q2 2024 related to office lease impairment.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from the financial statement issuance date.

• Topline data for PORTOLA trial expected in H1 2025; PALIZADE topline data expected mid-2026.

• Anticipates continued operating losses as clinical development progresses; expects increased expenses as trials advance.

• No product sales revenue expected in the near term; future revenue dependent on milestone and royalty payments from collaborations.

• Focused clinical resources on zetomipzomib development in autoimmune hepatitis and lupus nephritis.